Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Nov 8;132(19):2097-2100.
doi: 10.1182/blood-2018-05-851170. Epub 2018 Sep 20.

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma

Christoph Driessen  1 , Rouven Müller  2 , Urban Novak  3 , Nathan Cantoni  4 , Daniel Betticher  5 , Nicolas Mach  6 , Axel Rüfer  7 , Ulrich Mey  8 , Panagiotis Samaras  9 , Karin Ribi  10 , Lenka Besse  1 , Andrej Besse  1 , Catherine Berset  11 , Stephanie Rondeau  11 , Hanne Hawle  11 , Felicitas Hitz  1 , Thomas Pabst  3 , Thilo Zander  12
Affiliations
Clinical Trial

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma

Christoph Driessen et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: P.S. reports personal fees from Celgene, Takeda, Amgen, Novartis, and Janssen-Cilag outside the submitted work. The remaining authors declare no competing financial interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lokhorst HM, Plesner T, Laubach JP, et al. . Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207-1219. - PubMed
    1. Dimopoulos MA, Palumbo A, Corradini P, et al. . Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128(4):497-503. - PMC - PubMed
    1. Siegel DS, Martin T, Wang M, et al. . A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817-2825. - PMC - PubMed
    1. Kraus M, Bader J, Overkleeft H, Driessen C. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J. 2013;3(3):e103. - PMC - PubMed
    1. Gills JJ, Lopiccolo J, Tsurutani J, et al. . Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007;13(17):5183-5194. - PubMed